Major depressive disorder affects millions of people worldwide, yet a substantial number do not respond to standard antidepressant medications. When symptoms persist despite multiple treatment attempts, clinicians refer to the condition as treatment-resistant depression. In recent years, ketamine has gained attention as a fast-acting option for these patients, often reducing severe symptoms within days rather than weeks. While its clinical effects are well documented, researchers are still working to understand how ketamine produces these rapid changes in mood.
A new study adds an important piece to that puzzle by linking symptom improvement to subtle structural changes in the brain. Specifically, the findings suggest that amygdala volume changes after ketamine may track with relief from negative emotional symptoms in people with treatment-resistant depression.
Why The Amygdala Matters In Depression
The amygdala is a small, almond-shaped structure located deep in the brain’s temporal lobes. It plays a central role in processing emotions, especially fear, threat, and negative experiences. In people with depression, the amygdala often shows heightened activity, which may contribute to persistent feelings of sadness, anxiety, and emotional distress.
Previous brain imaging studies have shown that ketamine can reduce overactivity in the amygdala. However, whether ketamine also produces measurable changes in the structure of this region has been less clear. One challenge is that the amygdala is not a single unit but a collection of smaller subregions, each with different functions and connections.
Inside The Clinical Trial
To explore this question, researchers conducted a double-blind, randomized, placebo-controlled trial involving adults with treatment-resistant depression. Participants received either intravenous ketamine or a saline placebo twice a week for two weeks. High-resolution MRI scans were taken before treatment and again several days after the final infusion.
Using advanced imaging software, the research team divided the amygdala into distinct subregions rather than analyzing it as a whole. Depressive symptoms were measured using a standard clinical rating scale, with special attention to dysphoria, which includes feelings such as sadness, pessimism, and emotional unease.
Amygdala Volume Changes After Ketamine And Symptom Relief
The most striking finding emerged in the group treated with ketamine. Among these patients, reductions in the volume of the right laterobasal subregion of the amygdala were associated with greater improvements in dysphoric symptoms. In simple terms, as this specific part of the amygdala became smaller, patients reported feeling less unhappy and emotionally distressed.
Importantly, this relationship was not seen in the placebo group. This suggests the effect was not just a byproduct of feeling better but was linked to a neurobiological change triggered by ketamine itself. Other amygdala subregions and the left side of the amygdala did not show the same pattern.
What These Findings May Mean
The laterobasal amygdala is a key input center that receives information from the cortex, including areas involved in emotional regulation. In depression, communication between the prefrontal cortex and the amygdala is often disrupted, leading to poor control over negative emotional responses.
The researchers propose that ketamine may help restore this top-down regulation. As excessive emotional signaling decreases, the involved neural circuits may undergo subtle structural normalization. Rather than ketamine shrinking the amygdala in everyone, the study suggests that amygdala volume changes after ketamine reflect who is actually improving.
Limitations And Next Steps
This study was relatively small, and participants continued taking their existing antidepressant medications, which could influence brain structure. The follow-up period was also short, leaving open questions about whether these brain changes persist over time or predict long-term outcomes.
Even so, the findings highlight a promising direction for precision psychiatry. Identifying brain-based markers that track with symptom relief could help clinicians better predict who is most likely to benefit from ketamine and refine treatment strategies for patients with difficult-to-treat depression.
Citations:
1. Yonezawa K, Nakajima S, Hondo N, et al. The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression. Journal of Psychiatric Research. 2024. https://doi.org/10.1016/j.jpsychires.2024.01.012
2. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annual Review of Medicine. 2015;66:509–523. https://pubmed.ncbi.nlm.nih.gov/25341010/